KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating FGFR4 expression

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the major causes of death from cancer and has a very poor prognosis with few effective therapeutic options. Despite the approval of lenvatinib for the treatment of patients suffering from advanced HCC, only a small number of patients can benefit f...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Wenyun, Li, Songling, Qian, Yifei, Li, Linfeng, Wang, Fan, Tong, Yu, Li, Qianyu, Zhu, Zijun, Gao, Wei‐Qiang, Liu, Yanfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580016/
https://www.ncbi.nlm.nih.gov/pubmed/37846441
http://dx.doi.org/10.1002/ctm2.1452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580016/
https://www.ncbi.nlm.nih.gov/pubmed/37846441
http://dx.doi.org/10.1002/ctm2.1452

Ejemplares similares